European Medical Solutions Past Earnings Performance
Past criteria checks 0/6
European Medical Solutions has been growing earnings at an average annual rate of 49.6%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 61.6% per year.
Key information
49.6%
Earnings growth rate
75.7%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 61.6% |
Return on equity | -7.2% |
Net Margin | -1.7% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How European Medical Solutions makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 43 | -1 | 12 | 0 |
30 Sep 23 | 41 | -1 | 12 | 0 |
30 Jun 23 | 40 | -1 | 12 | 0 |
31 Mar 23 | 38 | -3 | 12 | 0 |
31 Dec 22 | 37 | -6 | 11 | 0 |
30 Sep 22 | 66 | -7 | 19 | 0 |
30 Jun 22 | 57 | -4 | 17 | 0 |
31 Mar 22 | 48 | -2 | 14 | 0 |
31 Dec 21 | 38 | 0 | 11 | 0 |
30 Sep 21 | 0 | 2 | 1 | 0 |
30 Jun 21 | 0 | 0 | 1 | 0 |
31 Mar 21 | 0 | -1 | 1 | 0 |
31 Dec 20 | 0 | -1 | 1 | 0 |
30 Sep 20 | 0 | -5 | 2 | 4 |
30 Jun 20 | 0 | -9 | 2 | 7 |
31 Mar 20 | 1 | -12 | 3 | 10 |
31 Dec 19 | 1 | -16 | 4 | 14 |
30 Sep 19 | 1 | -16 | 3 | 13 |
30 Jun 19 | 1 | -17 | 3 | 13 |
31 Mar 19 | 1 | -16 | 3 | 12 |
31 Dec 18 | 1 | -14 | 3 | 10 |
30 Sep 18 | 1 | -12 | 3 | 10 |
30 Jun 18 | 1 | -11 | 3 | 9 |
31 Mar 18 | 1 | -11 | 2 | 10 |
31 Dec 17 | 1 | -12 | 2 | 11 |
30 Sep 17 | 1 | -12 | 2 | 11 |
30 Jun 17 | 2 | -12 | 2 | 12 |
31 Mar 17 | 2 | -12 | 2 | 12 |
31 Dec 16 | 2 | -12 | 2 | 12 |
30 Sep 16 | 1 | -12 | 2 | 11 |
30 Jun 16 | 0 | -12 | 1 | 11 |
31 Mar 16 | 0 | -10 | 1 | 9 |
31 Dec 15 | 0 | -8 | 1 | 7 |
31 Dec 14 | 0 | -4 | 1 | 3 |
31 Dec 13 | 0 | -2 | 1 | 2 |
Quality Earnings: AS0 is currently unprofitable.
Growing Profit Margin: AS0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AS0 is unprofitable, but has reduced losses over the past 5 years at a rate of 49.6% per year.
Accelerating Growth: Unable to compare AS0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AS0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Return on Equity
High ROE: AS0 has a negative Return on Equity (-7.2%), as it is currently unprofitable.